Cargando…
Correlations between subfoveal choroidal thickness, macular thickness, and visual outcome in neovascular age-related macular degeneration using swept source OCT: insights from intravitreal aflibercept treatment
BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of visual impairment among individuals aged 50 and above, often resulting in irreversible vision loss (1). Currently, antiangiogenic therapy is the primary treatment approach for neovascular AMD (2). The choroid has gained signifi...
Autores principales: | Beraldo, Daniel P., Rezende, Marcussi P., Alexander, João G., Polido, Júlia, Belfort, Rubens, Cabral, Thiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652476/ https://www.ncbi.nlm.nih.gov/pubmed/37968771 http://dx.doi.org/10.1186/s40942-023-00506-4 |
Ejemplares similares
-
Subfoveal choroidal thickness in diabetic macular edema
por: Mohamed, Dalia Mohamed Fawzy, et al.
Publicado: (2019) -
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
por: Moradian, Siamak, et al.
Publicado: (2023) -
Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks
por: Esen, Ebru, et al.
Publicado: (2015) -
Subfoveal Choroidal Thickness and Treatment Outcomes of Intravitreal Aflibercept for Branch Retinal Vein Occlusion
por: Sakanishi, Yoshihito, et al.
Publicado: (2021) -
CHANGES IN SUBFOVEAL CHOROIDAL THICKNESS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT THERAPY FOR DIABETIC MACULAR EDEMA
por: Moon, Ka Young, et al.
Publicado: (2021)